Insulin Storage in Europe
A comment to Grajower et al., Eli Lilly, and Novo Nordisk
- Marco Gallo, MD12,
- Marco Comoglio, MD13,
- Alberto De Micheli, MD14,
- Luca Monge, MD15 and
- Giacomo Vespasiani, MD16
- 1AMD (Associazione Medici Diabetologi) scientific information website board (www.infodiabetes.it) Turin, Italy
- 2Diabetes Unit, Chivasso Civic Hospital, Turin, Italy
- 3Diabetes Service, Moncalieri, Turin, Italy
- 4Diabetes Unit, San Martino Hospital, Genoa, Italy
- 5Diabetes Unit, CTO Hospital, Turin, Italy
- 6Diabetology and Metabolic Disorders Center, Madonna del Soccorso Hospital, San Benedetto del Tronto, Ascoli Piceno, Italy
- Address correspondencereprint requests to Marco Gallo, MD, Diabetes Unit, Chivasso Civic Hospital—ASL7, Corso Galileo Ferraris, 3, 10034 Chivasso, Turin, Italy. E-mail: diabetologia{at}asl7.to.it
The commentary by Grajower et al. (1) raised important questions concerning the storage of an opened insulin vial, prefilled syringe, or cartridge. This is a very important topic because, as the author states, due to contradictory information on this subject, most physicians are not aware of the real effectiveness of insulin once it is opened.
Individual responses from the three pharmaceutical companies that supply insulin revealed different storage indications for every type of insulin they produce, depending on the particular formulation of insulin, its method of …
